MaaT013
Phase 3Small molecule
MaaT013 is one of 50 small molecule programs targeting Refractory. It is currently in Phase 3.
2
Indications
3
Total Trials
1
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
42 competitors in Graft Versus Host Disease
#DrugCompanyPhaseTrials
1Trexall
Jazz PharmaceuticalsApproved
Neoral
NovartisApproved
Medrol
PfizerApproved
Selzentry
GSKApproved
Nipent
PfizerApproved
Gleevec
NovartisApproved
Olumiant
Eli LillyApproved
Defitelio
Jazz PharmaceuticalsApproved
Qvar
SSchering-Plough
Approved
Cellcept
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MaaT013. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMaaT Pharma